TipRanks
Advertisement
Advertisement
Verismo Showcases Early SynKIR-310 Data, Signals Potential Step-Change in CAR T for B-Cell Lymphomas
PremiumPrivate CompaniesVerismo Showcases Early SynKIR-310 Data, Signals Potential Step-Change in CAR T for B-Cell Lymphomas
6M ago
Verismo Reports Encouraging First-in-Human Data for SynKIR-110 in Solid Tumors
Premium
Private Companies
Verismo Reports Encouraging First-in-Human Data for SynKIR-110 in Solid Tumors
6M ago
Verismo to Unveil First-in-Human KIR-CAR Data for SynKIR-110 and SynKIR-310 at AACR 2026
Premium
Private Companies
Verismo to Unveil First-in-Human KIR-CAR Data for SynKIR-110 and SynKIR-310 at AACR 2026
6M ago
Verismo Therapeutics Secures $28 Million to Advance KIR-CAR Trials Ahead of Key 2026 Data Readout
PremiumPrivate CompaniesVerismo Therapeutics Secures $28 Million to Advance KIR-CAR Trials Ahead of Key 2026 Data Readout
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―